loading.........
Sydney, Mar 22, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.
To view the video interview, please visit:
http://www.abnnewswire.net/press/en/96630/anr
To view the Pitt Street Research Report - "Following the Gut" , please visit:
http://abnnewswire.net/lnk/33S39548
About Anatara Lifesciences Limited
Related Companies
Anatara Lifesciences Limited
ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms. To view the video interview, please visit:
http://www.abnnewswire.net/press/en/96630/anr
To view the Pitt Street Research Report - "Following the Gut" , please visit:
http://abnnewswire.net/lnk/33S39548
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
|
||
|
Related Companies
Anatara Lifesciences Limited
ABN Newswire
